AP 402
Alternative Names: AP-402Latest Information Update: 08 May 2025
At a glance
- Originator AP Biosciences
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 29 Apr 2025 Adverse events, pharmacodynamics and pharmacokinetics data from a preclinical trial in Solid tumours released by AP Biosciences
- 22 Apr 2025 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in Australia (IV) (NCT06669975)
- 28 Feb 2025 Therapeutic Goods Administration (TGA) Australia approves IND application for AP 402 in Solid tumours